How does A278650's PS Ratio compare to its peers?

A278650 is good value based on its Price-To-Sales Ratio (3.7x) compared to the peer average (20x).

How does A278650's PS Ratio compare vs other companies in the KR Life Sciences Industry?

A278650 is good value based on its Price-To-Sales Ratio (3.7x) compared to the KR Life Sciences industry average (3.8x).

What is A278650's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate A278650's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of A278650 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate A278650's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

HLB bioStepLtd (KOSDAQ:A278650) - Stock Price, News & Analysis

A278650 Stock Overview

Provides various test services. More details

A278650 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Risk Analysis

Earnings have declined by 36.8% per year over past 5 years

Shareholders have been diluted in the past year

HLB bioStep Co.,Ltd. Competitors

Macrogen

KOSDAQ:A038290

₩160.7b

Cellivery Therapeutics

KOSDAQ:A268600

₩244.9b

NanoEntek

KOSDAQ:A039860

₩107.6b

Curiox Biosystems

KOSDAQ:A445680

₩313.2b

Price History & Performance

Summary of all time highs, changes and price drops for HLB bioStepLtd
Historical stock prices
Current Share Price	₩2,160.00
52 Week High	₩4,705.00
52 Week Low	₩1,953.00
Beta	0.41
11 Month Change	-5.05%
3 Month Change	-13.43%
1 Year Change	-19.10%
33 Year Change	-16.21%
5 Year Change	n/a
Change since IPO	-46.74%

Does HLB bioStepLtd (KOSDAQ:278650) Have A Healthy Balance Sheet?

Oct 21

Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?

Jul 17

HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely

May 22

Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%

Mar 29

Recent updates

Does HLB bioStepLtd (KOSDAQ:278650) Have A Healthy Balance Sheet?

Oct 21

Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?

Jul 17

HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely

May 22

Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%

Mar 29

Shareholder Returns

	A278650	KR Life Sciences	KR Market
7D	6.7%	-9.0%	-2.8%
1Y	-19.1%	33.1%	-3.4%

Return vs Industry: A278650 underperformed the KR Life Sciences industry which returned 33.1% over the past year.

Return vs Market: A278650 underperformed the KR Market which returned -3.4% over the past year.

Price Volatility

Is A278650's price volatile compared to industry and market?
A278650 volatility
A278650 Average Weekly Movement	7.2%
Life Sciences Industry Average Movement	8.8%
Market Average Movement	5.7%
10% most volatile stocks in KR Market	11.5%
10% least volatile stocks in KR Market	2.7%

Stable Share Price: A278650 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A278650's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2012	151	In-Sung Jeong	hlbbiostep.com

HLB bioStep Co.,Ltd. provides various test services. It offers platform technology services, such as cell-enzyme-based screening, xenograft assay, mitogenic effect test, vaccine antigen, antibody titration, cytokine, MRNA expression, trachea relaxation assay, carrageenan, adjuvant induced paw edema, antipyretic, anti-pain test, isolated blood vessel screening, fibrin plate lysis screening, ferric chloride induced model, food diet induced model, gastric acid secretion, emesis model, MIC test, post antibody effect, enzyme assay, systemic, local infection model, PK study, chemical, transgenic animal, osteoblast-like cell line screening, bone formation marker, and biomarker.

HLB bioStep Co.,Ltd. Fundamentals Summary

How do HLB bioStepLtd's earnings and revenue compare to its market cap?
A278650 fundamental statistics
Market cap	₩181.86b
Earnings (TTM)	-₩6.15b
Revenue (TTM)	₩49.17b

3.7x

P/S Ratio

-29.6x

P/E Ratio

Is A278650 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A278650 income statement (TTM)
Revenue	₩49.17b
Cost of Revenue	₩16.26b
Gross Profit	₩32.90b
Other Expenses	₩39.05b
Earnings	-₩6.15b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-73.01
Gross Margin	66.92%
Net Profit Margin	-12.50%
Debt/Equity Ratio	28.5%

How did A278650 perform over the long term?

See historical performance and comparison

A278650 Stock Overview

Risk Analysis

HLB bioStep Co.,Ltd. Competitors

KOSDAQ:A038290

₩160.7b

KOSDAQ:A268600

₩244.9b

KOSDAQ:A039860

₩107.6b

KOSDAQ:A445680

₩313.2b

Price History & Performance

Recent News & Updates

Does HLB bioStepLtd (KOSDAQ:278650) Have A Healthy Balance Sheet?

Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?

HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely

HLB bioStep Co.,Ltd. (KOSDAQ:A278650) announces an Equity Buyback for KRW 3,000 million worth of its shares.

HLB bioStep Co.,Ltd. announced that it expects to receive KRW 1.438165744 billion in funding from Kangstem Biotech Co., Ltd.

Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%

Recent updates

Does HLB bioStepLtd (KOSDAQ:278650) Have A Healthy Balance Sheet?

Is HLB bioStepLtd (KOSDAQ:278650) Using Debt Sensibly?

HLB bioStep Co.,Ltd. (KOSDAQ:278650) Shares May Have Slumped 33% But Getting In Cheap Is Still Unlikely

HLB bioStep Co.,Ltd. (KOSDAQ:A278650) announces an Equity Buyback for KRW 3,000 million worth of its shares.

HLB bioStep Co.,Ltd. announced that it expects to receive KRW 1.438165744 billion in funding from Kangstem Biotech Co., Ltd.

Subdued Growth No Barrier To HLB bioStep Co.,Ltd. (KOSDAQ:278650) With Shares Advancing 29%

Full year 2023 earnings released: ₩2.00 loss per share (vs ₩14.00 loss in FY 2022)

Here's Why HLB bioStepLtd (KOSDAQ:278650) Has A Meaningful Debt Burden

HLB bioStep Co.,Ltd. (KOSDAQ:A278650) announces an Equity Buyback for KRW 2,000 million worth of its shares.

New minor risk - Share price stability

HLB bioStep Co.,Ltd. (KOSDAQ:A278650) announces an Equity Buyback for KRW 3,000 million worth of its shares.

HLB bioStep Co.,Ltd. (KOSDAQ:A278650) announces an Equity Buyback for KRW 3,000 million worth of its shares.

Upcoming dividend of ₩22.22 per share

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Upcoming dividend of ₩150 per share

Investor sentiment improved over the past week

With EPS Growth And More, KNOTUSLtd (KOSDAQ:278650) Is Interesting

What Kind Of Investors Own Most Of KNOTUS Co.,Ltd (KOSDAQ:278650)?

Is KNOTUSLtd (KOSDAQ:278650) Using Too Much Debt?

Investors Who Bought KNOTUSLtd (KOSDAQ:278650) Shares A Year Ago Are Now Up 26%

New 90-day high: ₩32,300

Investor sentiment improved over the past week

Should We Be Delighted With KNOTUS Co.,Ltd's (KOSDAQ:278650) ROE Of 15%?

New 90-day high: ₩26,700

Investor sentiment improved over the past week

Is Now The Time To Put KNOTUSLtd (KOSDAQ:278650) On Your Watchlist?

Market pulls back on stock over the past week

New 90-day low: ₩23,050

Shareholder Returns

Price Volatility

About the Company

HLB bioStep Co.,Ltd. Fundamentals Summary

3.7x

-29.6x

Earnings & Revenue